Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens

The optimal antiviral regimen for hepatitis C virus (HCV) genotype 4 is still a subject of investigation. The report in this issue of Health Science Reports by Asselah and colleagues investigated the additional benefit of extending treatment duration of the ombitasvir/paritaprevir/ritonavir plus rib...

Descripción completa

Detalles Bibliográficos
Autor principal: Toyoda, Hidenori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427055/
https://www.ncbi.nlm.nih.gov/pubmed/30937390
http://dx.doi.org/10.1002/hsr2.106
Descripción
Sumario:The optimal antiviral regimen for hepatitis C virus (HCV) genotype 4 is still a subject of investigation. The report in this issue of Health Science Reports by Asselah and colleagues investigated the additional benefit of extending treatment duration of the ombitasvir/paritaprevir/ritonavir plus ribavirin regimen to up to 24 weeks for patients with HCV genotype 4 and compensated cirrhosis.

Ejemplares similares